PRESS RELEASE published on 04/21/2026 at 07:30, 4 months 27 days ago Terms of availability of the preparatory documents for the GM Sensorion provides Preliminary Documents for the Combined Shareholders' General Meeting of May 11, 2026. Shareholders urged to participate in a critical meeting addressing new therapies for hearing loss disorders Biotechnology Shareholders' Meeting Gene Therapy Sensorion Hearing Loss
BRIEF published on 03/23/2026 at 07:35, 5 months 26 days ago Sensorion continues its development in gene therapy for deafness Gene Therapy Congenital Deafness Audiogene Sense-501 Sense-601
BRIEF published on 03/23/2026 at 07:35, 5 months 26 days ago Sensorion Updates on Audiogene Trial and Advances GJB2-GT Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 03/18/2026 at 07:35, 6 months ago Sensorion Reports 2025 Results and Corporate Updates Financial Results Gene Therapy Sensorion Hearing Loss Sanofi Investment
PRESS RELEASE published on 03/18/2026 at 07:30, 6 months ago Inside Information / News release on accounts, results Sensorion reports full-year 2025 results, provides corporate update, and announces release of annual report. Key milestones in gene therapies for hearing loss. Financial highlights and future expectations highlighted Financial Highlights Full-year Results Sensorion Gene Therapies Future Milestones
BRIEF published on 02/17/2026 at 07:35, 7 months 1 day ago Sensorion announces changes in its management Change Of Direction Sensory Auditory Therapy Sanofi Financing Medical Pipeline
BRIEF published on 02/17/2026 at 07:35, 7 months 1 day ago Leadership Transition at Sensorion amid Strategic Focus on Hearing Loss Therapies Biotechnology Gene Therapy Leadership Change Sensorion Hearing Loss
PRESS RELEASE published on 02/17/2026 at 07:30, 7 months 1 day ago Inside Information / Other news releases Sensorion announces Nawal Ouzren stepping down as CEO for personal reasons. Amit Munshi to serve as Interim CEO. Sanofi-led financing for pipeline assets Leadership Changes Sanofi Sensorion Amit Munshi Nawal Ouzren
BRIEF published on 02/06/2026 at 07:35, 7 months 12 days ago Sensorion to Participate in ARO 49th Annual Midwinter Meeting Biotechnology Gene Therapy Sensorion Hearing Loss ARO Meeting
PRESS RELEASE published on 02/06/2026 at 07:30, 7 months 12 days ago Inside Information / Other news releases Sensorion to present SENS-601 gene therapy at ARO 49th Annual Midwinter Meeting in Puerto Rico Gene Therapy Sensorion Hearing Loss SENS-601 ARO 49th Annual Midwinter Meeting
Published on 09/18/2026 at 06:30, 2 hours 34 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 8 hours 9 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 8 hours 39 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 10 hours 49 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/18/2026 at 08:40, 23 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 1,000 million Convertible Bonds due 2030 (ISIN DE000A30V5R1 – Common Code 258943848 – German Securities Code (WKN) A30V5R)
Published on 09/18/2026 at 08:40, 24 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 500 million Convertible Bonds due 2029 (ISIN DE000A3MP437 – Common Code 238511097 – German Securities Code (WKN) A3MP43)
Published on 09/18/2026 at 08:37, 27 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 750 million Convertible Bonds due 2028 (ISIN DE000A3H2WQ0 – Common Code 220637387 – German Securities Code (WKN) A3H2WQ)
Published on 09/18/2026 at 08:31, 32 minutes ago EQS-Adhoc: The Grounds Real Estate Development AG: 2025 consolidated revenue within target range; 2025 consolidated EBIT below forecast; outlook for fiscal year 2026
Published on 09/18/2026 at 08:10, 54 minutes ago NORMA Group successfully completes second public share buyback offer with a repurchase volume of approximately EUR 208 million
Published on 09/17/2026 at 17:40, 15 hours 24 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 15 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 2 days 2 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
